Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel
Completed
- Conditions
- Malignant Glioma
- Registration Number
- NCT05486247
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Brief Summary
Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Diagnosis of high grade glioma based on tissue biopsy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel April 2019 - December 2021 The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel
- Secondary Outcome Measures
Name Time Method